Effects of ramosetron on the postoperative bowel function recovery

Effects of continuously administered ramosetron after laparoscopy-assisted gastrectomy on the postoperative recovery of bowel functions

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001324

Enrollment

Registered

2014-12-23

Start date

2012-05-16

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : After obtaining informed consent, patients scheduled for elective laparoscopy-assisted gastrectomy will be randomly allocated into either control group, low-dose ramosetron group, or high-dose

0 to 2 hours, 2 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients, aged 20 to 70, scheduled for elective laparoscopy-assisted gastrectomy American Society of Anesthesiologists class 1 or 2

Exclusion criteria

Exclusion criteria: Functional gastrointestinal disease Medication affecting gastrointestinal motility Administration of antiemetic medication within 24 h before surgery Addiction to opioids Pregnancy or breast-feeding Body mass index =30 kg/m2 Additional operative procedures other than gastrectomy or gastrointestinal anastomosis Conversion to open gastrectomy Postoperative leakage at the anastomosis site Duration of operation >5 h Uncontrolled diabetes mellitus Severe cardiovascular, renal, or hepatic disease Inability to communicate

Design outcomes

Primary

Measure	Time frame
Time to the first passage of flatus	—

Secondary

Measure	Time frame
Time to the first passage of feces;Time to soft diet intake;Postoperative nausea/vomiting;Postoperative pain;Headache, dizziness	—

Countries

Korea, Republic of

Contacts

Public ContactSang Hyun Hong

The Catholic University of Korea, Seoul St. Mary's Hospital

Outcome results